Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | ESR1 | P03372 | 1/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.50 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29611658 | 1.00 | NAPRT (0.69) | NAPRTCYP1A2CYP3A4CYP2C9ESR1 | |
| Hydrochloric Acid SCHEMBL1978920 | 0.98 | NAPRT (0.67) | NAPRTCYP1A2CYP3A4CYP2C9ESR1 | |
| SCHEMBL3253168 | 0.83 | NAPRT (0.74) | NAPRTCYP1A2CYP3A4CYP2C9CYP19A1 | |
| SCHEMBL4682021 | 0.83 | NAPRT (0.62) | NAPRTCYP1A2CYP3A4CYP2C9ESR1 | |
| SCHEMBL48609 | 0.82 | NAPRT (1.00) | NAPRTCYP1A2CYP3A4CYP2C9RECQL | |
| SCHEMBL15515595 | 0.82 | NAPRT (0.71) | NAPRTCYP1A2CYP3A4CYP2C9CYP19A1 | |
| SCHEMBL29430342 | 0.82 | NAPRT (1.00) | NAPRTCYP1A2CYP3A4CYP2C9RECQL | |
| SCHEMBL13196041 | 0.81 | CYP1A2 (0.62) | NAPRTCYP1A2CYP3A4CYP2C9RECQL | |
| SCHEMBL9630106 | 0.81 | ACACB (0.58) | CYP1A2CYP3A4CYP2C9CYP19A1RECQL | |
| SCHEMBL30917345 | 0.81 | NAPRT (0.65) | NAPRTCYP1A2CYP3A4CYP2C9ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 352 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108484595-B | Simple synthesis method of asthma medicine Fevipiprant | 天津科技大学 | 2021-03-30 | — | — | CN | claimed |
| CN-108484595-A | A kind of succinct synthetic method of asthmatic medicament Fevipiprant | 天津科技大学 | 2018-09-04 | — | — | CN | claimed |
| CN-1635877-A | Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance | NEUROSEARCH AS (DK) | 2005-07-06 | — | — | CN | claimed |
| EP-4688772-A1 | BIARYL DERIVATIVES AND RELATED USES | Moma Therapeutics, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260015360-A1 | BIARYL DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS, INC. | 2026-01-15 | — | — | US | disclosed |
| US-12522618-B2 | Copper complexes for treatment of neurodegenerative disorders | ALS THERAPY DEVELOPMENT INSTITUTE (US) | 2026-01-13 | — | — | US | disclosed |
| US-20240368195-A1 | COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | ALS THERAPY DEVELOPMENT INST (US) | 2024-11-07 | — | — | US | disclosed |
| WO-2024211834-A1 | BIARYL DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS, INC. (US) | 2024-10-10 | — | — | WO | disclosed |
| CN-118742337-A | Wound dressing | 爱适瑞卫生健康产品有限公司 | 2024-10-01 | — | — | CN | disclosed |
| US-12012422-B2 | Copper complexes for treatment of neurodegenerative disorders | ALS THERAPY DEVELOPMENT INSTITUTE (US) | 2024-06-18 | — | — | US | disclosed |
| WO-2023250513-A1 | 13-MEMBERED MACROLIDE COMPOUNDS FOR TREATING DISEASES MEDIATED BY ABNORMAL PROTEIN TRANSLATION | ZIKANI THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| US-4312875-A | 5-(Pyridinyl)-6-(lower-alkyl)-2(1H)-pyridinones, 1,2-dihydro-2-oxo-5-(pyridinyl)-6-(lower-alkyl)nicotinic acids and lower-alkyl esters thereof, and cardiotonic use thereof | STERLING DRUG INC. (US) | 1982-01-26 | — | — | US | disclosed |
| US-4309537-A | Production of imidazo[4,5-b]pyridin-2-ones or thiones | STERLING DRUG INC. (US) | 1982-01-05 | — | — | US | disclosed |
| US-4305948-A | N-Hydroxy-1,2-dihydro-2-oxo-5-(pyridinyl)-nicotinimidamide and their cardiotonic use | STERLING DRUG INC. (US) | 1981-12-15 | — | — | US | disclosed |
| US-4297360-A | 5-(Pyridinyl)pyridine-2,3-diamines, preparation thereof and their cardiotonic use | STERLING DRUG INC. (US) | 1981-10-27 | — | — | US | disclosed |
| US-4294837-A | 1,3-Dihydro-6-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones and -imidazo[4,5-b]pyridine-2-thiones and their cardiotonic use | STERLING DRUG INC. (US) | 1981-10-13 | — | — | US | disclosed |
| US-4276293-A | Compositions and their preparation | STERLING DRUG INC. (US) | 1981-06-30 | — | — | US | disclosed |
| US-4265895-A | 1,2-Dihydro-5-pyridinyl-3H-pyrazolo[3,4-b]pyridin-3-ones and their use as cardiotonics | STERLING DRUG INC. (US) | 1981-05-05 | — | — | US | disclosed |
| US-4264603-A | 5-(Pyridinyl)-1H-pyrazolo[3,4-b]pyridine-3-amines, their use as cardiotonics and their preparation | STERLING DRUG INC. (US) | 1981-04-28 | — | — | US | disclosed |
| US-4264612-A | Lower-alkyl 2-halo-5-(pyridinyl)nicotinates, their preparation and use as cardiotonics | STERLING DRUG INC. (US) | 1981-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015360-A1 | BIARYL DERIVATIVES AND RELATED USES | POLB, POLA1, POLN | NAPRT 2119/4885CYP1A2 558/4885CYP3A4 448/4885 |
| US-12012422-B2 | Copper complexes for treatment of neurodegenerative disorders | SOD1, SMN1; SMN2, CLN6 | NAPRT 2997/4885CYP1A2 3778/4885CYP3A4 4471/4885 |
| US-20240368195-A1 | COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | SOD1, SMN1; SMN2, CLN6 | NAPRT 2997/4885CYP1A2 3778/4885CYP3A4 4471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.